Picture Berlin Partner Hotspot for Startups 650x80px
Collaboration › Details

Merus–Credit Suisse: investor conference, 201609 supply service Merus presents at Credit Suisse Antibody Day 2016 in New York


Period Period 2016-09-07
Region Region New York, NY
  Country United States (USA)
Organisations Partner, 1st Merus N.V. (Nasdaq: MRUS)
  Group Merus (Group)
  Partner, 2nd Credit Suisse (Group)
  Today Credit Suisse Group AG
Products Product Credit Suisse Antibody Day 2016 New York
  Product 2 Biclonics® antibody
Persons Person Logtenberg, Ton (Merus BV 200601 CEO)
  Person 2 Minarovich, Kimberly (Argot Partners 201608)

Merus N.V.. (8/31/16). "Press Release: Merus to Participate in Upcoming Investor Conferences". Utrecht.

Merus N.V. (NASDAQ:MRUS), a clinical-stage immuno-oncology company developing innovative bispecific antibody therapeutics, today announced that the Company will participate in the following upcoming investor conferences:

> Ton Logtenberg, CEO, will present at the 2016 Credit Suisse Antibody Day on Wednesday, September 7 at 2:40 PM ET at Credit Suisse's offices at One Madison Avenue in New York City.

> Management will participate in investor meetings at Citi’s 11th Annual Biotech Conference on Thursday, September 8 at the Mandarin Oriental in Boston.

A live webcast of the Credit Suisse presentation will be available on the Investor page of the Company's website. An archived presentation will be available for 90 days.

About Merus N.V.

Merus is a clinical-stage immuno-oncology company developing innovative full length human bispecific antibody therapeutics, referred to as Biclonics®. Biclonics® are based on the full-length IgG format, are manufactured using industry standard processes and have been observed in preclinical studies to have several of the same features of conventional monoclonal antibodies, such as long half-life and low immunogenicity. Merus' lead bispecific antibody candidate, MCLA-128, is being evaluated in a Phase 1/2 clinical trial in Europe as a potential treatment for HER2-expressing solid tumors. Merus' second bispecific antibody candidate, MCLA-117, is being developed as a potential treatment for acute myeloid leukemia. The Company also has a pipeline of proprietary bispecific antibody candidates in preclinical development, including MCLA-158, which is designed to bind to cancer stem cells and is being developed as a potential treatment for colorectal cancer and other solid tumors, and Biclonics® designed to bind to various combinations of immunomodulatory molecules, including PD-1 and PD-L1.


Merus N.V.
Shelley Margetson –
+31 (0)30 253 8800

Argot Partners
Kimberly Minarovich –

Merus N.V.

Record changed: 2017-03-05


Picture [iito] Made Without Love 650x80px

More documents for Merus (Group)

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]


Picture [iito] Back into Ad 650x80px

» top